Serum osteocalcin

Williams DC, Paul DC, Black LJ (1991) Effects of estrogen and tamoxifen on serum osteocalcin levels in ovariectomized rats. Bone Miner 14 205-220... 

Consumption of soy foods (providing 60mg/day isoflavones) for 12 weeks by postmenopausal women has been found to significantly decrease clinical risk factors for osteoporosis (short-term markers of bone turnover) including decreased urinary M-telopeptide excretion (bone resorption marker) and increased serum osteocalcin (bone formation marker). Furthermore, consumption of a soy isoflavone supplement containing 61.8 mg of isoflavones for 4 weeks by postmenopausal Japanese women significantly decreased excretion of bone resorption markers. ... 

Measurement of serum osteocalcin is a useful marker for glucocorticoid-induced osteoporosis, and can be used alongside other measures noted below. 

Other methods, such as the fasting urinary hydroxypro-line/creatinine ratio, alkaline phosphatase activity, dualabsorption photometry of the hip, and serum osteocalcin measurements, can also be used, depending on an individual clinic s equipment and experience (SEDA-17, 447). 

Serum osteocalcin determinations appear to be a helpful marker to evaluate the effects of glucocorticoids on growth in children. 

The effects of inhaled glucocorticoids on bone mineral density (measured using dual X-ray absorptiometry of the spine and hip) and biochemical parameters were followed over 18 months. Mean serum osteocalcin concentrations were significantly lower in patients taking beclomethasone dipropionate or budesonide at doses of 800 micro-grams/day and more. However, bone mineral density of the lumbar spine and hip was not affected. The normal advancement of bone mineral density expected in growing children was not affected by inhaled glucocorticoids taken for 7-16 months (SEDA-22,184). 

In a 12-month, multicenter comparison of fluticasone propionate 250-500 micrograms/day with beclomethasone dipropionate 500-1000 micrograms/day, the two drugs had an equal therapeutic effect. Fluticasone propionate treatment resulted in a higher bone mineral density (assessed at the hip) and higher serum osteocalcin concentrations. 

In a prospective randomized comparison of the effects of fluticasone propionate 1000 micrograms/day and budesonide 1600 micrograms/day, over 1 year, bone mineral density measured in the spine was normal at the start of the study and increased slightly with time in both groups, as did serum osteocalcin concentration. 

M4. Masters, P. W., Jones, R. G., Purves, D. A., Cooper, E. H., and Cooney, J. M., Commercial assays for serum osteocalcin give clinically discordant results. Clin. Chem. 40, 358-363 (1994). 

Sokol , L., Booth, S, O Brien, M, Davidson, K. W Tsaioun, K. I., and Sadowski, J, A, (1997). Changes in serum osteocalcin, plasma phylloquinone, and urinary y-carboxyglutamic add in response to altered intakes of dietary phytloquinone in human sub ccts. Am., Gin. Nulr. 65, 779-784. 

Pietschmann P, Woloszczuk W, Panzer S, Kyrle P, Smolen J. Decreased serum osteocalcin levels in phenpro-coumon-treated patients. J Clin Endocrinol Metab 1988 66(5) 1071-4. 

Masters PW, Jones RG, Purves DA, Cooper EH, Cooney JM. Commercial assays for. serum osteocalcin give discordant results. Clin Chem 1994 40 358-63. 

Serum Osteocalcin Concentration and Serum Alkaline Phosphate (ALP) Isoenzyme Activities from Rats Fed Different Dietary Treatments ... 

Mean values for serum osteocalcin (n = 8) and serum alkaline phosphatase (ALP) activity (n = 8) within a row having different superscripts (rn, n for fet effect x, y for CLA effect A, B, Cfor interaction effect) are significantly different by two-way AN OVA and Duncan s multiple-range test (P< 0.05). The factorial design of dietary treatments allowed for an n = 16 in the statistical analysis of main effects. Results from the reference diet (SBO) were not included in the statistical analysis. 

In the current study, many factors that influence bone metabolism were altered by beef fat and CLA. The exception was ex vivo PGE2 production in tibia, which was not influenced by the lower level of CLA given to rats in this study. Interestingly, supplemental CLA at the dietary level of inclusion reduced serum osteocalcin in rats after 84 d of dietary treatment. Moreover, serum BALP activity... 

Biomarkers of bone turnover (serum osteocalcin, urinary DPD, serum BAP, etc.), typically included in studies with 3-6 month intervention duration, are also inconsistent in their response to soy product interventions these studies are described in more detail elsewhere (Coxam 2008). Meta-analyses of these trials revealed a moderate decrease in the bone resorption marker, urinary DPD, n = 887) but there were no effects on serum BAP or serum osteocalcin (Taku et al. 2010b). Intervention studies that include fracture as an outcome variable would be the optimum route for making conclusive assessments of the efficacy of SI in the prevention of OP, but very large numbers of participants would be required to achieve adequate statistical power. In the absence of data of this quality, the only recommendation is that including SF in the diet will not adversely affect bone health and might yield skeletal benefits in the long term. 

---